CJC-1295 (No DAC) / Ipamorelin / GHRP-2 Blend
Also known as: CJC-1295 & Ipamorelin & GHRP-2, Mod GRF 1-29 & Ipamorelin & GHRP-2, Mod GRF, Ipamorelin, GHRP-2
This three-peptide blend pairs CJC-1295 without DAC (a GHRH analog) with two ghrelin-mimetic secretagogues, Ipamorelin and GHRP-2, to maximize a clean, synergistic growth hormone pulse. All components are unapproved research peptides.
Last updated
Mechanism of Action
CJC-1295 without DAC is a modified GHRH(1-29) analog that binds the pituitary GHRH receptor and increases the amplitude of growth-hormone pulses. Ipamorelin and GHRP-2 are both GHS-R1a (ghrelin-receptor) agonists that stimulate GH release and reduce somatostatin tone, but Ipamorelin is highly selective with minimal cortisol or prolactin effect, while GHRP-2 is more potent and adds appetite drive. Layering a GHRH analog with two secretagogues amplifies the synergistic GH pulse through complementary receptor signaling, with Ipamorelin offering a cleaner profile and GHRP-2 adding potency. The short-acting no-DAC backbone keeps GH and IGF-1 release pulsatile and physiologic.
- Half-life
- Short across components: roughly 30 minutes for CJC-1295 no DAC, about 2 hours for Ipamorelin, and 15-30 minutes for GHRP-2
- Administration Routes
- subcutaneous
- Research Status
- Research Chemical
Reported Benefits
- Strong synergistic growth hormone release from layered pathways
- Ipamorelin contributes a clean, selective GH stimulus
- GHRP-2 adds potency and appetite support
- Raises downstream IGF-1 in research models
- Studied for recovery, lean mass, and body composition
- Short-acting design preserves physiologic GH pulsatility
Potential Side Effects
- Injection-site redness or irritation
- Water retention, tingling, or numbness
- Increased appetite and possible cortisol or prolactin rise (GHRP-2)
- Headache, flushing, or lightheadedness
- Possible reactive hypoglycemia
Common Dosing
For research use only and not medical advice: research protocols commonly combine roughly 100 mcg CJC-1295 (no DAC) with about 100 mcg Ipamorelin and 100 mcg GHRP-2 per subcutaneous administration, often dosed 1-2 times daily on an empty stomach. No validated human dosing exists.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Active or history of malignancy (GH and IGF-1 elevation)
- Uncontrolled diabetes or significant insulin resistance
- Pregnancy or breastfeeding
CJC-1295 (No DAC) / GHRP-2 Blend
This blend pairs CJC-1295 without DAC (Mod GRF 1-29), a GHRH analog, with GHRP-2, a growth hormone secretagogue, to synergistically stimulate pulsatile growth hormone release. Both are unapproved research peptides.
Ipamorelin
A selective ghrelin receptor agonist (growth hormone secretagogue) prized for stimulating GH release with minimal effect on cortisol or prolactin. Considered one of the gentler GH peptides.
GHRP-2
A growth hormone releasing peptide that strongly stimulates GH secretion via the ghrelin receptor. More potent than GHRP-6 with somewhat less appetite stimulation.
CJC-1295
A long-acting growth hormone releasing hormone (GHRH) analog that stimulates the pituitary to produce more growth hormone. Often paired with a ghrelin mimetic for synergistic GH release.
- View
Ipamorelin, the first selective growth hormone secretagogue
1998
- View
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
2006
- View
GHRP-2, GHRH and SRIF interrelationships during chronic administration of GHRP-2 to humans
1996